Shares of Horizon Pharma Inc. (NASDAQ:HZNP) traded down 2.4% on Monday . The stock traded as low as $18.79 and last traded at $18.97, with a volume of 1,927,739 shares trading hands. The stock had previously closed at $19.43.

Several analysts recently weighed in on the company. Citigroup Inc. assumed coverage on Horizon Pharma in a report on Wednesday, June 1st. They issued a “neutral” rating for the company. Zacks Investment Research raised Horizon Pharma from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a report on Monday, July 11th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $33.00 price objective (down from $34.00) on shares of Horizon Pharma in a report on Wednesday, August 10th. Vetr raised Horizon Pharma from a “hold” rating to a “buy” rating and set a $19.82 price objective for the company in a report on Tuesday, June 7th. Finally, Brean Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Horizon Pharma in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $29.15.

The stock has a 50-day moving average price of $20.34 and a 200 day moving average price of $17.47. The firm’s market capitalization is $3.03 billion.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. During the same period in the prior year, the business earned $0.39 earnings per share. The firm had revenue of $257.40 million for the quarter, compared to the consensus estimate of $235.43 million. The company’s revenue for the quarter was up 48.9% compared to the same quarter last year. On average, equities research analysts anticipate that Horizon Pharma Inc. will post $2.15 earnings per share for the current fiscal year.

In other news, Director Virinder Nohria sold 25,000 shares of Horizon Pharma stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $17.69, for a total transaction of $442,250.00. Following the transaction, the director now directly owns 189,836 shares of the company’s stock, valued at $3,358,198.84. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Jeffrey W. Sherman sold 2,900 shares of Horizon Pharma stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Horizon Pharma stock. Morgan Stanley boosted its position in Horizon Pharma Inc. (NASDAQ:HZNP) by 51.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 548,234 shares of the biopharmaceutical company’s stock after buying an additional 185,829 shares during the period. Morgan Stanley owned 0.34% of Horizon Pharma worth $11,881,000 at the end of the most recent reporting period.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.